MYGN Myriad Genetics Inc

Price (delayed)

$19.4

Market cap

$1.56B

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$0.11

Enterprise value

$1.48B

Myriad Genetics Inc., is a leading genetic testing and precision medicine company dedicated to transforming patient lives worldwide. Myriad discovers and commercializes genetic tests that: determine the risk of developing ...

Highlights
The EPS has soared by 94% YoY and by 69% from the previous quarter
The company's net income has surged by 94% YoY and by 70% QoQ

Key stats

What are the main financial stats of MYGN
Market
Shares outstanding
80.34M
Market cap
$1.56B
Enterprise value
$1.48B
Valuations
Price to earnings (P/E)
N/A
Price to book (P/B)
1.63
Price to sales (P/S)
2.28
EV/EBIT
N/A
EV/EBITDA
36.72
EV/Sales
2.17
Earnings
Revenue
$682.4M
EBIT
-$29.4M
EBITDA
$40.4M
Free cash flow
-$117.3M
Per share
EPS
-$0.11
Free cash flow per share
-$1.46
Book value per share
$11.87
Revenue per share
$8.52
TBVPS
$7.78
Balance sheet
Total assets
$1.26B
Total liabilities
$305.3M
Debt
$89.9M
Equity
$950.1M
Working capital
$261.4M
Liquidity
Debt to equity
0.09
Current ratio
2.57
Quick ratio
2.23
Net debt/EBITDA
-1.86
Margins
EBITDA margin
5.9%
Gross margin
71.4%
Net margin
-1.2%
Operating margin
-25%
Efficiency
Return on assets
-0.6%
Return on equity
-0.9%
Return on invested capital
-8%
Return on capital employed
-2.7%
Return on sales
-4.3%
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

MYGN stock price

How has the Myriad Genetics stock price performed over time
Intraday
2.05%
1 week
6.77%
1 month
3.69%
1 year
-39.47%
YTD
-29.71%
QTD
6.77%

Financial performance

How have Myriad Genetics's revenue and profit performed over time
Revenue
$682.4M
Gross profit
$487.1M
Operating income
-$170.3M
Net income
-$8.2M
Gross margin
71.4%
Net margin
-1.2%
The net margin has soared by 95% YoY and by 69% from the previous quarter
The company's net income has surged by 94% YoY and by 70% QoQ
The company's operating margin rose by 29% YoY and by 9% QoQ
The gross profit is up by 26% year-on-year

Growth

What is Myriad Genetics's growth rate over time

Valuation

What is Myriad Genetics stock price valuation
P/E
N/A
P/B
1.63
P/S
2.28
EV/EBIT
N/A
EV/EBITDA
36.72
EV/Sales
2.17
The EPS has soared by 94% YoY and by 69% from the previous quarter
MYGN's price to book (P/B) is 33% lower than its last 4 quarters average of 2.4 and 24% lower than its 5-year quarterly average of 2.1
The company's equity rose by 9% YoY
The P/S is 32% lower than the last 4 quarters average of 3.3 and 23% lower than the 5-year quarterly average of 2.9
Myriad Genetics's revenue has increased by 21% YoY

Efficiency

How efficient is Myriad Genetics business performance
MYGN's return on equity has surged by 95% year-on-year and by 69% since the previous quarter
Myriad Genetics's return on assets has surged by 94% YoY and by 70% QoQ
The ROS has soared by 87% YoY and by 41% from the previous quarter
The return on invested capital has surged by 80% year-on-year and by 42% since the previous quarter

Dividends

What is MYGN's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for MYGN.

Financial health

How did Myriad Genetics financials performed over time
The company's total liabilities fell by 34% YoY and by 13% QoQ
The quick ratio has increased by 22% year-on-year and by 6% since the previous quarter
The debt is 91% less than the equity
The debt to equity has dropped by 64% year-on-year and by 10% since the previous quarter
The debt has plunged by 59% YoY and by 2.6% from the previous quarter

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.